Temporomandibular Joint Inflammation Activates Glial and Immune Cells in Both the Trigeminal Ganglia and in the Spinal Trigeminal Nucleus

• Published in: Molecular pain Vol. 6; no. 1; p. 89
• Main Authors: Villa, Giovanni, Ceruti, Stefania, Zanardelli, Matteo, Magni, Giulia, Jasmin, Luc, Ohara, Peter T, Abbracchio, Maria P
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 10.12.2010; BioMed Central Ltd; Sage Publications Ltd; BioMed Central; SAGE Publishing
• Subjects: Animals; Care and treatment; Central Nervous System; Complications and side effects; Development and progression; Ganglia; Genetic aspects; Headaches; Immune System - pathology; Inflammation; Inflammation - metabolism; Inflammation Mediators - administration & dosage; Male; Neuroglia - metabolism; Neurons; Pain; Peripheral Nervous System; Physiological aspects; Rats; Rats, Sprague-Dawley; Rodents; Studies; Temporomandibular joint; Temporomandibular Joint - pathology; TNF inhibitors; Trigeminal Ganglion - pathology; Trigeminal Nucleus, Spinal - pathology; Tumors; United States
• ISSN: 1744-8069; 1744-8069
• DOI: 10.1186/1744-8069-6-89

Background: Glial cells have been shown to directly participate to the genesis and maintenance of chronic pain in both the sensory ganglia and the central nervous system (CNS). Indeed, glial cell activation has been reported in both the dorsal root ganglia and the spinal cord following injury or inflammation of the sciatic nerve, but no data are currently available in animal models of trigeminal sensitization. Therefore, in the present study, we evaluated glial cell activation in the trigeminal-spinal system following injection of the Complete Freund's Adjuvant (CFA) into the temporomandibular joint, which generates inflammatory pain and trigeminal hypersensitivity. Results: CFA-injected animals showed ipsilateral mechanical allodynia and temporomandibular joint edema, accompanied in the trigeminal ganglion by a strong increase in the number of GFAP-positive satellite glial cells encircling neurons and by the activation of resident macrophages. Seventy-two hours after CFA injection, activated microglial cells were observed in the ipsilateral trigeminal subnucleus caudalis and in the cervical dorsal horn, with a significant up-regulation of Iba1 immunoreactivity, but no signs of reactive astrogliosis were detected in the same areas. Since the purinergic system has been implicated in the activation of microglial cells during neuropathic pain, we have also evaluated the expression of the microglial-specific P2Y12 receptor subtype. No upregulation of this receptor was detected following induction of TMJ inflammation, suggesting that any possible role of P2Y12 in this paradigm of inflammatory pain does not involve changes in receptor expression. Conclusions: Our data indicate that specific glial cell populations become activated in both the trigeminal ganglia and the CNS following induction of temporomandibular joint inflammation, and suggest that they might represent innovative targets for controlling pain during trigeminal nerve sensitization.